Date: 2017-07-10
Type of information: Research agreement
Compound: fimaNAc technology (nucleic acid therapeutics delivery)
Company: PCI Biotech (Norway) undisclosed top-10 large pharma company
Therapeutic area: undisclosed
Type agreement: R&D - research
Action mechanism: drug delivery system (DDS)
Disease:
Details:
- • On September 10, 2015, PCI Biotech reported that it has signed an agreement with an undisclosed top-10 large pharma company, with the aim to evaluate synergistic effects of the PCI technology with their therapeutic nucleic acid technology. Initially, the purpose of the pre-clinical research program is to determine whether PCI has the potential to enhance the therapeutic effect of their nucleic acid technology platform.
- The current pre-clinical research agreement covers evaluation of technology compatibility and synergy based on in vitro studies. The costs related to the research collaboration will be covered by the pharma company, which is one of the global leaders in nucleic acid therapeutics. The companies will evaluate the data generated in this research collaboration and based on this explore the potential for a further partnership. The original evaluation period spans over 9 months, but may be further extended.
Financial terms:
Latest news:
- • On July 10, 2017, PCI Biotech announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over six months, until the end of 2017, and may be further extended.
- The aim of the extension is to further evaluate the synergistic effects of both parties' technology platforms and to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the therapeutic effect of the partner's nucleic acid therapeutic compounds.
Is general: Yes
